High blood pressure is the most common chronic disease in France: 1 in 3 people suffer from it (and half don’t know). Linked to abnormally high blood pressure in the blood vessels, this disease seems harmless because it is usually silent. It does, however, when not controlled, one of the main causes of cardiovascular or neurodegenerative complications (myocardial infarction, Stroke, sickness
Alzheimer’s...) However, 30% of patients diagnosed 30% do not respond, or insufficiently, to the treatments currently available.
A drop in blood pressure of – 4.7 mmHg on average
Researchers are therefore working on the development of a new class of drugs that targets blood pressure via three mechanisms. Firibastat has been tested on 34 patients with daytime blood pressure between 135/85 mmHg and 170/105 mmHg. Half of them received firibastat and the other half a placebo, for 4 weeks. For the next 4 weeks, the distribution of drugs was reversed.
The results of this trial, published in the Journal of hypertension, show that systolic blood pressure (SBP) was better controlled under firibastat with a fall in SBP of – 4.7 mmHg on average compared to +0.1 mmHg under placebo.
These good results gave the green light to another study, carried out in the United States on a group of more than 250 overweight hypertensive patients, often with drug-resistant hypertension.
Read also :
This method of breathing reduces blood pressure
Getting up at night to pee is a sign of hypertension